Brief: Eisai Projects Leqembi® Revenue To Total JPY 76.5 Billion For FY 2025
15/05/2025 06:14
May 15 (Reuters) - BioArctic AB BIOAb.ST: EISAI PROJECTS LEQEMBI® REVENUE TO TOTAL JPY 76.5 BILLION FOR FISCAL YEAR 2025 (APRIL 2025 - MARCH 2026) BIOARCTIC AB - EXPECTED TO RECEIVE SEK 510 M IN ROYALTY FROM LEQEMBI SALES Source text: ID:nWkr2CvvfT Further company coverage: [BIOAb.ST] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China